|Author(s)/Faculty: Arshad M. Khanani, MD, MA; Jennifer I. Lim, MD; Michael A. Singer, MD|
|Release Date: 5/25/2022||Expiration Date: 5/24/2023|
|Credit Type: CME / CME with ABO Continuing Certification ||Number of Credits: 1|
|Content Type: Video||Provider: |
|The need to identify alternate molecular targets for the management of retinal vascular diseases has been highlighted by the proportion of patients who have either a suboptimal or lack of response to intravitreal anti-vascular endothelial growth factor (VEGF) therapies. Other pathways that have demonstrated involvement in abnormal angiogenesis and increased vessel permeability within the eye, such as the angiopoietin/Tie2 pathway, are attractive targets. In this CME activity, experts in the field review the role of the angiopoietin/Tie2 pathway in retinal and choroidal vascular diseases as well as provide updates of the last clinical evidence regarding the safety and efficacy of injectable therapies that target the angiopoietin/Tie2 pathway in these patients.